UCB SA (EBR:UCB)
Belgium
· Delayed Price · Currency is EUR 256.40
+5.40 (2.15%)
At close: Mar 9, 2026
UCB SA Revenue
In the year 2025, UCB SA had annual revenue of 7.74B EUR with 25.83% growth. UCB SA had revenue of 4.25B in the half year ending December 31, 2025, with 59.74% growth.
Revenue
7.74B
Revenue Growth
+25.83%
P/S Ratio
6.17
Revenue / Employee
792.73K
Employees
9,765
Market Cap
47.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.74B | 1.59B | 25.83% |
| Dec 31, 2024 | 6.15B | 970.00M | 18.72% |
| Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
| Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
| Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| argenx SE | 3.62B |
| Financière de Tubize | 13.26K |
| Onward Medical | 2.72M |
| Hyloris Pharmaceuticals | 8.46M |
| European Medical Solutions | 49.47M |
| Celyad Oncology | 186.00K |
| BioSenic | -2.39M |
| Oxurion NV | 2.00K |
UCB SA News
- 5 days ago - Belgium's UCB in autoimmune drug deal with Antengene - Reuters
- 4 months ago - U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) - PRNewsWire